Eupraxia Pharmaceuticals Gets FDA Fast-Track Designation for EP-104IAR Study
By Robb M. Stewart
Eupraxia Pharmaceuticals said Tuesday the U.S. Food and Drug Administration has granted fast-track designation for the investigation of the company's lead product candidate, EP-104IAR, in the treatment of adults with osteoarthritis of the knee.
The clinical-stage biotechnology company said it continues to advance its ongoing Phase 2 trial evaluating EP-104IAR's safety and efficacy as a treatment candidate for knee osteoarthritis and expects to report top-line data results in the second quarter of this year.
The FDA's fast-track process is designed to help the development and speed the review of drugs that treat serious conditions and fill an unmet medical need.
In late May, Eupraxia said it reached the last patient to visit in its Phase 2 clinical trial of EP-104IAR for osteoarthritis, milestone toward the completion of the study.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 13, 2023 07:28 ET (11:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase